Our new study feom 13 centres in 9 countries included over 7,600 patients and ahows that p16+ patients do not all have the same outcomes. P16+ HPV- patiwnts do signfiicantly better than p16+ HPV- patientd, and so answering a debate that has taken place for over 20 years. This has importqnt implications for patient treatment.
To read more
